1
|
Włodarczyk J, Krajewska J, Talar M, Szeleszczuk Ł, Gurba A, Lipiec S, Taciak P, Szczepaniak R, Młynarczuk-Biały I, Fichna J. New gold(III) complexes TGS 121, 404, and 702 show anti-tumor activity in colitis-induced colorectal cancer: an in vitro and in vivo study. Pharmacol Rep 2024; 76:127-139. [PMID: 38082190 PMCID: PMC10830623 DOI: 10.1007/s43440-023-00558-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Revised: 11/10/2023] [Accepted: 11/13/2023] [Indexed: 02/02/2024]
Abstract
BACKGROUND Chronic inflammation in the course of inflammatory bowel disease may result in colon cancer, or colitis-associated colorectal cancer (CACRC). It is well established that CACRC is associated with oxidative stress and secretion of multiple pro-inflammatory cytokines, e.g. tumor necrosis factor-α. Recently, we proved that the administration of gold(III) complexes resulted in the alleviation of acute colitis in mice. The aim of the current study was to assess the antitumor effect of a novel series of gold(III) complexes: TGS 121, 404, 512, 701, 702, and 703. MATERIALS Analyzed gold(III) complexes were screened in the in vitro studies using colorectal cancer and normal colon epithelium cell lines, SW480, HT-29, and CCD 841 CoN, and in vivo, in the CACRC mouse model. RESULTS Of all tested complexes, TGS 121, 404, and 702 exhibited the strongest anti-tumor effect in in vitro viability assay of colon cancer cell lines and in in vivo CACRC model, in which these complexes decreased the total number of colonic tumors and macroscopic score. We also evidenced that the mechanism of action was linked to the enzymatic antioxidant system and inflammatory cytokines. CONCLUSIONS TGS 121, 404, and 702 present anti-tumor potential and are an attractive therapeutic option for colorectal cancer.
Collapse
Affiliation(s)
- Jakub Włodarczyk
- Department of Biochemistry, Chair of Biochemistry and Chemistry, Faculty of Medicine, Medical University of Łódź, Mazowiecka 5, 92-215, Lodz, Poland
- Department of General and Oncological Surgery, Faculty of Medicine, Medical University of Łódź, Pomorska 251, 92-213, Lodz, Poland
| | - Julia Krajewska
- Department of Biochemistry, Chair of Biochemistry and Chemistry, Faculty of Medicine, Medical University of Łódź, Mazowiecka 5, 92-215, Lodz, Poland
| | - Marcin Talar
- Department of Biochemistry, Chair of Biochemistry and Chemistry, Faculty of Medicine, Medical University of Łódź, Mazowiecka 5, 92-215, Lodz, Poland
| | - Łukasz Szeleszczuk
- Department of Organic and Physical Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-093, Warsaw, Poland
| | - Agata Gurba
- Department of Pharmacodynamics, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1 Str., 02-093, Warsaw, Poland
| | - Szymon Lipiec
- HESA at the Department for Histology and Embryology, Medical University of Warsaw, Chałubińskiego 5, 02-004, Warsaw, Poland
| | - Przemysław Taciak
- Department of Pharmacodynamics, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1 Str., 02-093, Warsaw, Poland
| | | | - Izabela Młynarczuk-Biały
- Department for Histology and Embryology, Medical University of Warsaw, Chałubińskiego 5, 02-004, Warsaw, Poland
| | - Jakub Fichna
- Department of Biochemistry, Chair of Biochemistry and Chemistry, Faculty of Medicine, Medical University of Łódź, Mazowiecka 5, 92-215, Lodz, Poland.
| |
Collapse
|